BLACKMORES LIMITED (BKL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

BKL - BLACKMORES LIMITED

FNArena Sector : Health & Nutrition
Year End: June
GICS Industry Group : Household & Personal Products
Index: ASX200 | ASX300 | ALL-ORDS

Blackmores is Australia's leading natural health supplement company manufacturing and marketing a range of food supplements, including vitamins, mineral and herb products. Founded in 1932, it became a public company in 1985.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$72.49

18 May
2022

-0.860

OPEN

$72.50

-1.17%

HIGH

$73.90

30,370

LOW

$71.86

TARGET
$82.932 14.4% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
EBO . MCP . API . EXL . SIG . CLV .
FNARENA'S MARKET CONSENSUS FORECASTS
BKL: 1
Title FY20
Actual		 FY21
Actual		 FY22
Forecast		 FY23
Forecast
EPS (cps) xxx 128.5 159.6 xxx
DPS (cps) xxx 71.0 89.7 xxx
EPS Growth xxx 24.1% 24.2% xxx
DPS Growth xxx N/A 26.4% xxx
PE Ratio xxx N/A 43.5 xxx
Dividend Yield xxx N/A 1.3% xxx
Div Pay Ratio(%) xxx 55.3% 56.2% xxx

Dividend yield today if purchased 3 years ago: 0.78%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.02

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 22/03 - ex-div 63c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx128.5
DPS All xxxxxxxxxxxxxxx71.0
Sales/Revenue xxxxxxxxxxxxxxx575.9 M
Book Value Per Share xxxxxxxxxxxxxxx1,926.9
Net Operating Cash Flow xxxxxxxxxxxxxxx58.7 M
Net Profit Margin xxxxxxxxxxxxxxx4.16 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Capital Employed xxxxxxxxxxxxxxx7.07 %
Return on Invested Capital xxxxxxxxxxxxxxx5.95 %
Return on Assets xxxxxxxxxxxxxxx4.27 %
Return on Equity xxxxxxxxxxxxxxx7.07 %
Return on Total Capital xxxxxxxxxxxxxxx11.64 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx43.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.2

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

28/02/2022

3

Hold

$80.00

10.36%

As part of the 1H results presentation, Blackmores guided to a meaningful uplift in 2H marketing spend, which Ord Minnett's expects 
will result in a material fall for the consensus earnings estimate. This comes despite a beat to the broker's 1H profit and dividend estimates.

The International division, and particularly Indonesia, contributed to the higher-than-expected sales result, explains the analyst. After amending earnings forecasts, the broker lowers its target to $80 from $87 and maintains its Hold rating.

The fully franked interim dividend was 63cps compared to 45cps forecast by Ord Minnett, which represented a payout ratio of 60% of underlying net profit.

This stock is not covered in-house by Ord Minnett. Instead, the broker whitelabels research by JP Morgan.

FORECAST
Ord Minnett forecasts a full year FY22 EPS of 162.00 cents.
Ord Minnett forecasts a full year FY23 EPS of 234.00 cents.

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Credit Suisse

xx/xx/xxxx

3

xxxxxxxxx xx xxxxxxx xxxx xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

BKL STOCK CHART

FNArena News on BKL

1
Rudi’s View: Risk Is Tangible, And On The Rise

Mar 10 2022 - Rudi's View
2
Australian Broker Call *Extra* Edition – Mar 08, 2022

Mar 08 2022 - Daily Market Reports
3
Rudi’s View: Too Many Distractions From Corporate Results

Mar 03 2022 - Rudi's View
4
Weekly Ratings, Targets, Forecast Changes – 25-02-22

Feb 28 2022 - Weekly Reports
5
FNArena Corporate Results Monitor – 25-02-2022

Feb 25 2022 - Australia

Latest Health & Nutrition News

1
Sigma Healthcare: Brokers Wary

Mar 31 2022 - Australia
2
Health & Wellness Boom On The ASX

Apr 29 2021 - Weekly Reports
3
M&A Now On Sigma Healthcare’s Agenda

Mar 24 2021 - Australia
4
McPherson’s Expands Into Herbal Health

Nov 04 2020 - Small Caps
5
Nine Ignored Companies Now Worth A Look

Sep 23 2020 - FYI
6
Next Week At A Glance – 14-18 Sep 2020

Sep 11 2020 - Weekly Reports
7
Sigma Farewells API, Heralds New Contract

Dec 17 2019 - Australia
8
Blackmores: Hopes Pinned On Restructuring

Nov 01 2019 - Australia
9
Blackmores Peps Up Its Strategy For China

Apr 17 2019 - Australia
10
API/Sigma Merger Plan Rears, Again

Dec 17 2018 - Australia